Rystiggo Purple Book BLA 761286

BLA number
761286
Proprietary names
Rystiggo
Proper names
rozanolixizumab-noli
Applicant
UCB, Inc.
Center
CDER
First observed release
2023-07-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Rystiggorozanolixizumab-noli351(a)280MG/2ML (140MG/ML)InjectionSubcutaneousSingle-Dose VialRxLicensed2023-06-26
002Rystiggorozanolixizumab-noli351(a)420MG/3ML (140MG/ML)InjectionSubcutaneousSingle-Dose VialRxLicensed2024-06-14
003Rystiggorozanolixizumab-noli351(a)560MG/4ML (140MG/ML)InjectionSubcutaneousSingle-Dose VialRxLicensed2024-06-14
004Rystiggorozanolixizumab-noli351(a)840MG/6ML (140MG/ML)InjectionSubcutaneousSingle-Dose VialRxLicensed2024-06-14

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2025-12-01N002Rystiggo351(a)RxUCB, Inc.
2025-12-01N003Rystiggo351(a)RxUCB, Inc.
2025-12-01N004Rystiggo351(a)RxUCB, Inc.
2023-11-01U001Rystiggo351(a)RxUCB, Inc.
2023-07-01N001Rystiggo351(a)RxUCB, Inc.

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2025-12-01002Rystiggo351(a)RxLicensed2024-06-14
2025-12-01003Rystiggo351(a)RxLicensed2024-06-14
2025-12-01004Rystiggo351(a)RxLicensed2024-06-14
2023-07-01001Rystiggo351(a)RxLicensed2023-06-26